Hypothesis

Chronic mTORC1 activation creates a mismatch between mitochondrial biogenesis and mitophagy, leading to accumulation of damaged ETC complexes and NAD+/NADH imbalance. We hypothesize that short, periodic intervals of mTORC1 inhibition (e.g., low‑dose rapamycin pulses) combined with sustained NAD+ precursor supplementation will transiently relieve the autophagy block while preserving enough anabolic signaling to drive functional mitochondrial turnover. This regimen should enable cells to cycle between a growth phase (biogenesis) and a cleanup phase (mitophagy) without the net suppression of protein synthesis that accompanies continuous mTORC1 inhibition, thereby improving OXPHOS efficiency, restoring NAD+/NADH homeostasis, and reducing senescent cell burden.

Mechanistic Rationale

1. mTORC1‑ULK1/TFEB axis – mTORC1 directly inhibits the ULK1/ATG13 complex and TFEB, blocking autophagosome formation and lysosomal biogenesis. A brief reduction in mTORC1 activity (≤2 h) is sufficient to de‑phosphorylate ULK1 and allow TFEB nuclear translocation, initiating mitophagy, while longer suppression (>6 h) diminishes PGC‑1α‑driven biogenesis. Pulsing thus creates a temporal window where clearance can occur before biogenesis is markedly reduced.
2. NAD+‑SIRT1‑mTORC1 feedback – Rising NAD+ activates SIRT1, which deacetylates and activates TSC2, thereby attenuating mTORC1 signaling. Supplementing with NAD+ precursors (e.g., NR or NMN) during the rapamycin‑off phase will enhance SIRT1 activity, reinforcing the autophagic state and promoting lysosomal acidification, which further supports mitophagy flux.
3. Mitochondrial quality control – Functional mitophagy removes mitochondria with low membrane potential, preventing the propagation of ROS‑damaged ETC subunits. When biogenesis follows a clearance phase, newly synthesized mitochondria are assembled from a healthier pool of components, improving coupling efficiency and NAD+ regeneration via oxidative phosphorylation.
4. Decoupling growth from senescence – Senescent cells exhibit a hyperactive mTORC1‑SASP loop. By intermittently lowering mTORC1 activity, we reduce SASP production without triggering the catabolic state that drives tissue wasting. The NAD+ boost further suppresses SASP via SIRT1‑mediated NF‑κB inhibition.

Testable Predictions

• In vitro: Human fibroblasts treated with 20 nM rapamycin for 2 h every 12 h, plus 250 µM NR continuously, will show (i) increased LC3‑II/I ratio and mitochondrial‑targeted Keima signal (indicating mitophagy) during rapamycin windows, (ii) elevated PGC‑1α and TFAM expression during off‑windows, and (iii) higher basal OCR and ATP production compared to constant rapamycin or NR alone.
• In vivo: Progeroid Ercc1‑/Δ mice receiving the same intermittent rapamycin/NR regimen (rapamycin 1 mg/kg i.p. twice weekly, NR 400 mg/kg chow) for 3 months will exhibit (a) reduced accumulation of mitochondria with low TMRE signal in liver and muscle, (b) improved NAD+/NADH ratio (measured by LC‑MS), (c) decreased p16^Ink4a^ and SA‑β‑gal positive cells, and (d) extended median lifespan versus vehicle or continuous rapamycin groups.
• Falsification: If intermittent rapamycin fails to increase mitophagy flux (no rise in mitochondrial Keima signal) or if NAD+ supplementation does not further enhance the effect, the hypothesis that temporal decoupling drives benefit would be refuted.

Significance

This hypothesis reframes mTORC1 not as a simple longevity switch but as a regulatable oscillator that, when pulsed in concert with NAD+ metabolism, can synchronize mitochondrial synthesis with quality control. It suggests a practical intervention strategy—timed rapamycin cycles with NAD+ boosters—that could improve metabolic health and delay aging‑related dysfunction without the deleterious effects of chronic mTORC1 inhibition.